产品详情
文献和实验
相关推荐
PROTACs
Induced Protein Degradation (PROTACs)
Controlling intracellular protein levels using small molecules
Carfilzomib/Kyprolis™
The next generation proteasome inhibitor
Chemical Biology
Exploring cell biology using small molecules
Identify and validate new drug targets
二十多年来，Crews 实验室一直在探索使用化学方法来控制细胞系统。 靶向蛋白质降解的新领域以及我们在蛋白酶体抑制剂 carfilzomib / Kyprolis® 和蛋白水解靶向嵌合体 (PROTAC) 开发中的作用就是例证。 我们继续对双功能小分子的设计和开发感兴趣，以利用生物系统。
PROTACs：诱导靶向蛋白质降解
我们的蛋白水解靶向嵌合体 (PROTAC) 技术劫持了细胞质量控制机制，以标记不需要的细胞内蛋白质进行降解。 PROTACs 具有比 siRNA 和 CRISPR 更好的药学特性，通过降解致病蛋白提供了一种新的治疗方式。
For over two decades, the Crews Lab has explored using chemical approaches to control cellular systems. This is best exemplified by the new field of Targeted Protein Degradation and our role in the development of the proteasome inhibitor carfilzomib / Kyprolis® and Proteolysis Targeting Chimera (PROTACs). We continue to be interested in the design and development of bifunctional small molecules to harness biological systems.
PROTACs: Inducing Targeted Protein Degradation
Our Proteolysis Targeting Chimera (PROTAC) technology hijacks the cellular quality control machinery to tag unwanted intracellular proteins for degradation. With better pharmaceutic properties than siRNA and CRISPR, PROTACs offer a new therapeutic modality by degrading pathogenic proteins.
Induced Protein Degradation (PROTACs)
Controlling intracellular protein levels using small molecules
Carfilzomib/Kyprolis™
The next generation proteasome inhibitor
Chemical Biology
Exploring cell biology using small molecules
Identify and validate new drug targets
二十多年来，Crews 实验室一直在探索使用化学方法来控制细胞系统。 靶向蛋白质降解的新领域以及我们在蛋白酶体抑制剂 carfilzomib / Kyprolis® 和蛋白水解靶向嵌合体 (PROTAC) 开发中的作用就是例证。 我们继续对双功能小分子的设计和开发感兴趣，以利用生物系统。
PROTACs：诱导靶向蛋白质降解
我们的蛋白水解靶向嵌合体 (PROTAC) 技术劫持了细胞质量控制机制，以标记不需要的细胞内蛋白质进行降解。 PROTACs 具有比 siRNA 和 CRISPR 更好的药学特性，通过降解致病蛋白提供了一种新的治疗方式。
For over two decades, the Crews Lab has explored using chemical approaches to control cellular systems. This is best exemplified by the new field of Targeted Protein Degradation and our role in the development of the proteasome inhibitor carfilzomib / Kyprolis® and Proteolysis Targeting Chimera (PROTACs). We continue to be interested in the design and development of bifunctional small molecules to harness biological systems.
PROTACs: Inducing Targeted Protein Degradation
Our Proteolysis Targeting Chimera (PROTAC) technology hijacks the cellular quality control machinery to tag unwanted intracellular proteins for degradation. With better pharmaceutic properties than siRNA and CRISPR, PROTACs offer a new therapeutic modality by degrading pathogenic proteins.
北京美科美生物技术开发有限公司
代理商实名认证
钻石会员
入驻年限：11年
